Affiliation:
1. Washington State University, Spokane, WA, USA
Abstract
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.
Reference11 articles.
1. Roctavian (valoctocogene roxaparvovec-rvox) [prescribing information]. BioMarin Pharmaceutical Inc; June 2023.
2. WFH Guidelines for the Management of Hemophilia, 3rd edition
3. Purple Book: Database of Licensed Biological Products. Food and Drug Administration. Updated October 24, 2023. Accessed October 30, 2023. https://purplebooksearch.fda.gov/
4. Hemlibra (emicizumab-kxwh) [prescribing information]. Genentech Inc; March 2023.
5. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A